Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

NCT01497444 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer
Liver Cancer

Interventions

DRUG: hypoxia-activated prodrug TH-302
DRUG: sorafenib tosylate

Sponsor

Alliance for Clinical Trials in Oncology

Collaborators

[object Object]
[object Object]